Farmaforum Partnering Day 2025

18 Sept 2025 | Madrid, Spain

Register
Register
Register

ProductUpdated on 30 June 2025

AKicell Monocyte Cell Therapy

Pablo Garcia de la Riva Mestre

CEO at M2RLAB

Madrid, Madrid, Spain

About

Akicell is the first application of an autologous advanced cell therapy platform that is produced at a centralized facity. It is a therapy that does not fight against a specific molecular mechanism or pathway, but favors a decrease of inflammation and activates simultaneously mechanisms regenerating damaged tissue, thus avoiding or significantly decreasing the processes of necrosis and fibrosis that follow kidney aggression. We gather the patient's blood and return our medicine to the hospital within 36 hours to treat the patient with a GMP quality ready to administer medicine.

Applies to

  • Pharmaceutical industry
  • Laboratory industry

Organisation

M2RLAB

SME

Madrid, Spain

Similar opportunities